Five things for pharma marketers to know: Monday, June 6, 2016

Share this content:

1. Researchers say some multiple-myeloma patients should be prescribed multiple drugs, which raises concerns about costs. Adding Johnson & Johnson's Darzalex to an older two-drug cocktail increases efficacy but could cost at least $180,000 for one year of treatment. (WSJ)

2. Kite Pharma and Juno Therapeutics, which are both developing CAR-T therapies, say their experimental cancer drugs may be approved in 2017. The therapies, which are mainly being tested in blood cancers, harness the immune system's T cells to fight cancers. (Reuters)

3. The FDA approved Allergan's Byvalson, a hypertension treatment. The therapy, which combines Bystolic and valsartan, is expected to be available in the second half of the year.

4. A biosimilar version of Roche's Herceptin is comparable in safety and effectiveness to the brand-name drug, according to data presented at ASCO. Mylan is developing the breast-cancer biosimilar, Myl-1401O. (WSJ)

5. Martin Shkreli is facing new charges. Prosecutors allege that he used employees and consultants to conceal control of his stock while he was serving as CEO of Retrophin. (Bloomberg)

Share this content:
Scroll down to see the next article